NCT04369053

Prevention of Colorectal Cancer Through Multiomics Blood Testing

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 48,995 (actual)
• Sponsor: Freenome Holdings Inc. · Industry
• Sex: All
• Age: 45 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

Detailed description

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this prospective multi-center observational study is to validate a blood-based test for the detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

Conditions

• Colon Cancer
• Rectal Cancer
• Colon Neoplasm
• Colon Diseases
• Colon Lesion
• Colon Polyp
• Colorectal Cancer
• Polyp
• Adenoma
• Rectal Diseases
• Gastrointestinal Tract Cancers

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Freenome test	Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.

Timeline

• Start date: 2020-05-20
• Primary completion: 2024-02-29
• Completion: 2024-02-29
• First posted: 2020-04-30
• Last updated: 2025-12-26
• Results posted: 2025-12-05

Locations

148 sites across 2 countries: United States, Canada